Preterm labor: Current pharmacotherapy options for tocolysis

Elvira O G Van Vliet, Elisabeth M. Boormans, Thomas S. De Lange, Ben W. Mol, Martijn A. Oudijk

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Introduction: In the developed world, preterm birth is in quantity and in severity the most important issue in obstetric care. Adverse neonatal outcome is strongly related to gestational age at delivery. Since the pathophysiological mechanism of preterm birth is not yet completely unraveled, the development of successful preventive strategies is hampered. When preterm labor is actually threatening, current pharmacological therapies focus on inhibition of preterm contractions. This allows for transportation of the mother to a center with a neonatal intensive care unit and administration of corticosteroids to enhance fetal lung maturation. Globally, however, large practice variation exists. Areas covered: The aim of this review is to provide an overview of current pharmacological therapies for preterm labor. Expert opinion: For the initial tocolysis, the use of atosiban or nifedipine for 48 h is recommended based on the largest effectiveness and most favorable side effect profile. However, since data that convincingly indicate the beneficial effect of tocolytics on neonatal outcome are lacking, it might well be that tocolytics are ineffective. The role of progesterone in treatment of acute tocolysis is limited, but it might play a role in the prevention of preterm labor or as sensitizer for other tocolytic agents.

LanguageEnglish
Pages787-797
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number6
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Pharmacotherapy
  • Preterm birth
  • Preterm labor
  • Tocolytics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Van Vliet, E. O. G., Boormans, E. M., De Lange, T. S., Mol, B. W., & Oudijk, M. A. (2014). Preterm labor: Current pharmacotherapy options for tocolysis. Expert Opinion on Pharmacotherapy, 15(6), 787-797. https://doi.org/10.1517/14656566.2014.889684
Van Vliet, Elvira O G ; Boormans, Elisabeth M. ; De Lange, Thomas S. ; Mol, Ben W. ; Oudijk, Martijn A. / Preterm labor : Current pharmacotherapy options for tocolysis. In: Expert Opinion on Pharmacotherapy. 2014 ; Vol. 15, No. 6. pp. 787-797.
@article{e462365ebd3f415dade33ec5113f6cc2,
title = "Preterm labor: Current pharmacotherapy options for tocolysis",
abstract = "Introduction: In the developed world, preterm birth is in quantity and in severity the most important issue in obstetric care. Adverse neonatal outcome is strongly related to gestational age at delivery. Since the pathophysiological mechanism of preterm birth is not yet completely unraveled, the development of successful preventive strategies is hampered. When preterm labor is actually threatening, current pharmacological therapies focus on inhibition of preterm contractions. This allows for transportation of the mother to a center with a neonatal intensive care unit and administration of corticosteroids to enhance fetal lung maturation. Globally, however, large practice variation exists. Areas covered: The aim of this review is to provide an overview of current pharmacological therapies for preterm labor. Expert opinion: For the initial tocolysis, the use of atosiban or nifedipine for 48 h is recommended based on the largest effectiveness and most favorable side effect profile. However, since data that convincingly indicate the beneficial effect of tocolytics on neonatal outcome are lacking, it might well be that tocolytics are ineffective. The role of progesterone in treatment of acute tocolysis is limited, but it might play a role in the prevention of preterm labor or as sensitizer for other tocolytic agents.",
keywords = "Pharmacotherapy, Preterm birth, Preterm labor, Tocolytics",
author = "{Van Vliet}, {Elvira O G} and Boormans, {Elisabeth M.} and {De Lange}, {Thomas S.} and Mol, {Ben W.} and Oudijk, {Martijn A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1517/14656566.2014.889684",
language = "English",
volume = "15",
pages = "787--797",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "6",

}

Van Vliet, EOG, Boormans, EM, De Lange, TS, Mol, BW & Oudijk, MA 2014, 'Preterm labor: Current pharmacotherapy options for tocolysis', Expert Opinion on Pharmacotherapy, vol. 15, no. 6, pp. 787-797. https://doi.org/10.1517/14656566.2014.889684

Preterm labor : Current pharmacotherapy options for tocolysis. / Van Vliet, Elvira O G; Boormans, Elisabeth M.; De Lange, Thomas S.; Mol, Ben W.; Oudijk, Martijn A.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 6, 01.01.2014, p. 787-797.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Preterm labor

T2 - Expert Opinion on Pharmacotherapy

AU - Van Vliet, Elvira O G

AU - Boormans, Elisabeth M.

AU - De Lange, Thomas S.

AU - Mol, Ben W.

AU - Oudijk, Martijn A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Introduction: In the developed world, preterm birth is in quantity and in severity the most important issue in obstetric care. Adverse neonatal outcome is strongly related to gestational age at delivery. Since the pathophysiological mechanism of preterm birth is not yet completely unraveled, the development of successful preventive strategies is hampered. When preterm labor is actually threatening, current pharmacological therapies focus on inhibition of preterm contractions. This allows for transportation of the mother to a center with a neonatal intensive care unit and administration of corticosteroids to enhance fetal lung maturation. Globally, however, large practice variation exists. Areas covered: The aim of this review is to provide an overview of current pharmacological therapies for preterm labor. Expert opinion: For the initial tocolysis, the use of atosiban or nifedipine for 48 h is recommended based on the largest effectiveness and most favorable side effect profile. However, since data that convincingly indicate the beneficial effect of tocolytics on neonatal outcome are lacking, it might well be that tocolytics are ineffective. The role of progesterone in treatment of acute tocolysis is limited, but it might play a role in the prevention of preterm labor or as sensitizer for other tocolytic agents.

AB - Introduction: In the developed world, preterm birth is in quantity and in severity the most important issue in obstetric care. Adverse neonatal outcome is strongly related to gestational age at delivery. Since the pathophysiological mechanism of preterm birth is not yet completely unraveled, the development of successful preventive strategies is hampered. When preterm labor is actually threatening, current pharmacological therapies focus on inhibition of preterm contractions. This allows for transportation of the mother to a center with a neonatal intensive care unit and administration of corticosteroids to enhance fetal lung maturation. Globally, however, large practice variation exists. Areas covered: The aim of this review is to provide an overview of current pharmacological therapies for preterm labor. Expert opinion: For the initial tocolysis, the use of atosiban or nifedipine for 48 h is recommended based on the largest effectiveness and most favorable side effect profile. However, since data that convincingly indicate the beneficial effect of tocolytics on neonatal outcome are lacking, it might well be that tocolytics are ineffective. The role of progesterone in treatment of acute tocolysis is limited, but it might play a role in the prevention of preterm labor or as sensitizer for other tocolytic agents.

KW - Pharmacotherapy

KW - Preterm birth

KW - Preterm labor

KW - Tocolytics

UR - http://www.scopus.com/inward/record.url?scp=84896460563&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.889684

DO - 10.1517/14656566.2014.889684

M3 - Review article

VL - 15

SP - 787

EP - 797

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -